Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON PLC (ICLR) delivers essential clinical research services across 100+ countries, supporting pharmaceutical and biotechnology development through all trial phases. This news hub provides investors and industry professionals with timely updates on operational milestones, financial performance, and strategic initiatives shaping global drug development.
Access authoritative reporting on regulatory submissions, partnership announcements, and clinical trial advancements directly impacting ICON's market position. Our curated feed eliminates information fragmentation by centralizing earnings calls, governance updates, and technology implementations critical for evaluating contract research organizations.
Key coverage areas include phase III trial initiations, FDA/EMA regulatory interactions, acquisition strategies, and capacity expansion projects. Bookmark this page for real-time updates on ICON's patient recruitment innovations and quality control enhancements that maintain compliance with evolving global standards.
ICON (NASDAQ: ICLR) reported Q3 2025 results with revenue $2,042.8M (up 1.3% vs Q2) and adjusted EBITDA $396.7M (19.4% of revenue).
GAAP net income was $2.4M ($0.03 diluted EPS) and adjusted net income was $258.8M ($3.31 adjusted diluted EPS). A $165.3M goodwill impairment was recorded against the Data Solutions unit. Net debt was $2.9B (net debt/adjusted EBITDA 1.8x). Free cash flow for Q3 was $333.9M and YTD $687.2M. ICON repurchased $250M of stock in Q3 and updated 2025 revenue guidance to $8,050–$8,100M with adjusted diluted EPS guidance of $13.00–$13.20.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has scheduled its third quarter 2025 financial results release for Wednesday, October 22, 2025, after market close. The company will host a conference call and webcast to discuss the results on Thursday, October 23, 2025, at 8:00am ET.
A replay of the webcast will be made available approximately one hour after the call concludes. Investors can access the webcast through the "Events" section of ICON's investor relations website.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, announced a significant leadership transition. Dr. Steve Cutler will retire as CEO, with Barry Balfe, current Chief Operating Officer, appointed as the new CEO effective October 1, 2025.
Balfe, who joined ICON's executive leadership team in 2019, has served as President of Functional Services, President of Pharma Solutions, and most recently as COO since January 2025. Dr. Cutler will remain on the board as a non-executive director to ensure a smooth transition after his 14-year tenure with the company.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced upcoming presentations at two major healthcare investor conferences. COO Barry Balfe will present at the Baird 2025 Global Healthcare Conference on September 10, 2025 at 1:25 pm ET. Additionally, CEO Dr. Steve Cutler will participate in the Deutsche Bank 2025 Healthcare Summit on September 11, 2025.
Live webcasts of the presentations, where available, will be accessible through the Investor section of ICON's website under the "Events" tab.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, announced that shareholders approved all resolutions at its Annual General Meeting held on July 22, 2025. The meeting saw strong participation with 59,889,939 total votes cast across various resolutions.
Key approvals included the re-election of all eight board members, with particularly strong support for Anne Whitaker (99.4% approval) and Dr. Steve Cutler (99% approval). Shareholders also ratified EY as auditors and approved measures regarding share allotment, pre-emption rights, and overseas market purchases.
ICON plc (NASDAQ: ICLR) reported its Q2 2025 financial results with mixed performance indicators. The company achieved gross business wins of $2.97 billion, up 10.6% from Q1 2025, and net business wins of $2.06 billion with a book-to-bill ratio of 1.02.
Q2 revenue reached $2.02 billion, representing a 0.8% increase from Q1 2025 but a 4.8% decrease year-over-year. Net income was $183.0 million ($2.30 per diluted share), up 30.7% from Q2 2024. The company's adjusted EBITDA was $396.0 million (19.6% of revenue).
ICON has expanded its share repurchase program by $500 million to a total of $1 billion and updated its full-year 2025 guidance, projecting revenue between $7.85-$8.15 billion and adjusted EPS of $13.00-$14.00.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has been recognized as a top-performing CRO for phase 1 clinical trials according to an independent Industry Standard Research (ISR) report. The company achieved the highest overall sponsor satisfaction score of 7.4/10 among large CROs.
The comprehensive analysis, based on feedback from 159 industry professionals, revealed ICON's superior performance across 17 operational metrics, leading in 14 categories. The company demonstrated excellence in delivery metrics, staff characteristics, and accessibility metrics. Notably, ICON was the only large CRO to improve across all four brand strength metrics compared to 2024, marking its sixth consecutive year of outperforming weighted average scores in phase 1 trials.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has received multiple prestigious awards in the first half of 2025. The company earned the AI Project of the Year Award for its enterprise-grade AI Assistant implementation, and was recognized on TIME Magazine's sustainability rankings, placing 57th out of 500 companies globally.
Notable achievements include being named Best CRO in APAC at the 2025 Asia Pacific Biopharma Excellence Awards and recognition as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards. Additionally, over 30 ICON employees received awards at the PharmaTimes International Clinical Researcher of the Year competition.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced that its CEO, Dr. Steve Cutler, will present at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for Wednesday, June 4, 2025, at 10:40 AM CT. The company will provide updates and links to the live webcast, where available, on the Investor section of their website under the "Events" tab.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
